SAB Biotherapeutics: Chardan Capital Reiterates Buy Rating, Raises PT to $20.

SAB Biotherapeutics: Chardan Capital Reiterates Buy Rating, Raises PT to $20.

Chardan Capital has reiterated its buy rating for SAB Biotherapeutics (SABSW) and raised its price target (PT) to $20. The investment firm maintains its positive outlook on the clinical-stage biopharmaceutical company, citing its innovative approach to developing human polyclonal immunotherapeutic antibodies and its strong pipeline of therapeutic candidates [1].

SAB Biotherapeutics focuses on addressing immune system disorders and infectious diseases through its proprietary DiversitAb platform. The company's lead product candidate, SAB-142, is currently under Phase 1 trials for delaying the onset or progression of type 1 diabetes, while SAB-176 is in Phase 2a development for the treatment or prevention of severe influenza [2].

Chardan Capital's analyst noted that SAB Biotherapeutics' recent earnings report, which showed earnings per share (EPS) of ($0.56) for the quarter, was better than expected. The firm believes that the company's strong pipeline and potential market opportunities for its products will drive growth and support its valuation [1].

Despite the recent decrease in stock price, Chardan Capital remains bullish on SAB Biotherapeutics. The firm's analysts pointed out that the company's negative net margin and negative trailing twelve-month return on equity are temporary setbacks that do not reflect its long-term growth prospects. They also noted that the company's high insider ownership and improving investor sentiment, as evidenced by a decrease in short interest, are positive indicators for the stock [1].

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/SABS/
[2] https://www.stocktitan.net/news/SABSW/